Discussion Guide — Chapter 4

1. "Semaglutide is not a better GLP-1 receptor agonist than GLP-1. So what exactly did the chemists do?"

Listen for: the reframe from potency to persistence. Then push: if evolution already optimized the receptor interaction, what does that tell us about where the remaining opportunities in peptide drug development actually are? (Delivery, duration, and selectivity across related receptors — which is Chapter 9's subject.)

2. "One of semaglutide's three modifications does nothing for the patient. Why is it there?"

A small question with a large payoff. Listen for: students working out that a mixture of attachment isomers would be a manufacturing and quality-control problem. Then ask what would happen if a manufacturer skipped it — you get two products in one vial, nearly impossible to separate. That is Chapter 34's subject arriving early, and students who see it here read that chapter much better.

3. "Oral semaglutide throws away about 99% of every tablet. Is that good engineering?"

Listen for: a real argument. Yes: it works, it is needle-free, the drug is safe enough that the waste is tolerable, and 1% consistent beats 15% variable. No: it is expensive, the administration requirements are burdensome and easy to get wrong, and adherence to a fasting protocol is a real-world problem the trials may understate. Both positions are defensible.

4. "Both inhaled insulins worked and both failed. What is the right unit of success for a drug?"

Listen for: the separation of pharmacological success from therapeutic success. Then the harder question: who decides? A drug that works and that nobody uses has failed by one standard and succeeded by another, and the standards belong to different people — the scientist, the regulator, the company, the patient. This is a good rehearsal for Chapter 12.

5. "A gray-market vial costs a fraction of the prescription. What is the difference actually made of?"

Listen for: the §4.8 list — no sterile fill-finish, no formulation science, no QC system, no clinical evidence, no regulatory oversight, no device, no cold chain guarantee. Then the honest complication: some of the price difference is market structure and patent exclusivity, and pretending otherwise insults students who already know it. The goal is a student who can say both sentences.

6. "The delivery filter would have rejected oral semaglutide before it existed. Should we still use it?"

The best question in the chapter and the one to end on. Listen for: the distinction between "nobody has solved this" and "this cannot be solved," and for the idea of burden-shifting — the filter's job is to make the seller explain, cheaply and immediately. A student who abandons the filter because it is fallible has learned the wrong lesson; so has one who treats it as conclusive.